Formosa Pharmaceuticals (TPE:6838) EPS (Basic): NT$-0.54 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6838 Formosa Pharmaceuticals Inc TPE:6838
48 GF Score
Price NT$23.60
GF Value NT$14.25
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Formosa Pharmaceuticals EPS (Basic)?

Formosa Pharmaceuticals TPE:6838 -1.67% 48 EPS (Basic) is NT$-0.54 as of Dec. 2025. GuruFocus rates TPE:6838 with a GF Score™ of 48/100 and a GF Value™ of NT$14.25 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Formosa Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was NT$-0.31. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.54.

Formosa Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2025 was NT$-0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.54.

Formosa Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2025 was NT$-0.31. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.54.

During the past 3 years, the average EPS without NRI Growth Rate was 47.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 29.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Formosa Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 47.80% per year. The lowest was -9.60% per year. And the median was 17.90% per year.

Formosa Pharmaceuticals  (TPE:6838) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Formosa Pharmaceuticals EPS (Basic) Related Terms

Formosa Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Formosa Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formosa Pharmaceuticals EPS (Basic) Chart

Formosa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -4.21 -3.86 -2.59 -1.43 -0.55

Formosa Pharmaceuticals Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 -0.27 0.43 -0.39 -0.31
TPE:6838
48GF Score
Formosa Pharmaceuticals Inc TPE:6838
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Formosa Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Formosa Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-83.565-0)/150.977
=-0.55

Formosa Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-47.965-0)/150.977
=-0.32

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$-0.54 mean?
Formosa Pharmaceuticals (TPE:6838) has a EPS (Basic) of NT$-0.54 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Formosa Pharmaceuticals and its competitors.
Is Formosa Pharmaceuticals' EPS (Basic) too high?
Formosa Pharmaceuticals' current EPS (Basic) is NT$-0.54. Overall, Formosa Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Formosa Pharmaceuticals' EPS (Basic) compare to VRTX and REGN?
Formosa Pharmaceuticals' EPS (Basic) of NT$-0.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Formosa Pharmaceuticals and its competitors. Formosa Pharmaceuticals's current EPS (Basic) is NT$-0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formosa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Formosa Pharmaceuticals (TPE:6838) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.25, compared to a current price of NT$23.60 — trading 65.6% above its estimated fair value. The current EPS (Basic) is NT$-0.54. Formosa Pharmaceuticals' overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Formosa Pharmaceuticals (TPE:6838), the current EPS (Basic) is NT$-0.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formosa Pharmaceuticals (TPE:6838) Overvalued in 2026?

Based on GuruFocus' analysis, Formosa Pharmaceuticals stock appears to be overvalued. The current stock price of NT$23.60 is trading 65.6% above its estimated GF Value™ of NT$14.25. GuruFocus considers Formosa Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TPE:6838:

  • EPS (Basic): NT$-0.54
  • GF Value™: NT$14.25 vs. price of NT$23.60 (65.6% above fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the TPE:6838 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formosa Pharmaceuticals Business Description

Address No. 57, Fuxing North Road, 8th Floor-6, Songshan District, Taipei, TWN, 105
Formosa Pharmaceuticals Inc is engaged in new drug development and transfers. Its Product pipeline includes TSY-110, TSY-120, TSY-310, APP13007 and APP13002.
48GF Score

Get the complete analysis for TPE:6838

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$23.60
Price
NT$14.25
GF Value